PER-056-02已完成未知
CLINICAL PHASE II STUDY OF IROFULVEN IN COMBINATION WITH IRINOTECAN IN PATIENTS WITH ADVANCED SOLID TUMORS GASTROINTESTINALES
MGI PHARMA, INC.,0 个研究点目标入组 0 人开始时间: 2002年8月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with advanced gastrointestinal solid tumors without standard chemotherapy treatment or progressed to standard chemotherapy.
- •Disease measurable / evaluable by the RECIST criteria.
- •Age 18 years.
- •ECOG Performance Status (PS): 0-1
- •Life expectancy> 3 months.
排除标准
- •Previous chemotherapy with topoisomerase I inhibitors
- •Previous intestinal obstruction / subostruction not completely resolved or chronic diarrhea, chronic enteropathy, extensive intestinal resection (> hemicolectomy).
- •Patients with radiant treatment in more than 35% of the bone marrow after admission to the study.
- •Presence of any serious concomitant systemic disorder incompatible with the study.
- •Presence of any disorder of the central nervous or psychiatric system that may hinder the participation of the patient in the study.
研究者
相似试验
进行中（未招募）
1 期
Phase II study of Irofulven in AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients, who have a Drug Response Predictor (DRP™) indicating a high likelihood of response to IrofulveEUCTR2017-003549-72-DKOncology Venture Aps27
已完成
2 期
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerNCT00053365National Cancer Institute (NCI)61
已完成
2 期
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)Metastatic Castration-Resistant Prostate Cancer PatientsNCT03643107Allarity Therapeutics15
已完成
2 期
Study of Irofulven in Patients With Hormone-refractory Prostate CancerProstate CancerNCT00124566Eisai Inc.135
进行中（未招募）
1 期
Evaluate the safety and the efficacy of Vemurafenib/PEG-interferon in melanoma patientsEvaluate the safety and the efficacy of Vemurafenib/PEG-interferon combination and the IFNAR1 upregulation lead by this treatment in advanced melanoma patients harboring the V600BRAF mutationMedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2013-003730-33-ITFondazione Melanoma ONLUS48